DiaMedica Therapeutics Past Earnings Performance
Past criteria checks 0/6
DiaMedica Therapeutics's earnings have been declining at an average annual rate of -15.7%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been declining at an average rate of 98.2% per year.
Key information
-15.7%
Earnings growth rate
10.2%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -98.2% |
Return on equity | -38.0% |
Net Margin | n/a |
Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
May 16We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
Jan 12FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold
Jul 06We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Jun 16We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
Jan 04DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.
Nov 05DiaMedica: Undercovered Stroke Drug Company With Decent Data
Jun 13We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth
May 01Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?
Feb 13We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn
Jan 09DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Revenue & Expenses BreakdownBeta
How DiaMedica Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -19 | 8 | 13 |
30 Sep 23 | 0 | -18 | 8 | 12 |
30 Jun 23 | 0 | -17 | 7 | 10 |
31 Mar 23 | 0 | -15 | 7 | 9 |
31 Dec 22 | 0 | -14 | 6 | 8 |
30 Sep 22 | 0 | -13 | 6 | 7 |
30 Jun 22 | 0 | -14 | 5 | 8 |
31 Mar 22 | 0 | -13 | 5 | 8 |
31 Dec 21 | 0 | -14 | 5 | 9 |
30 Sep 21 | 0 | -15 | 5 | 10 |
30 Jun 21 | 0 | -14 | 5 | 10 |
31 Mar 21 | 0 | -13 | 5 | 9 |
31 Dec 20 | 0 | -12 | 4 | 8 |
30 Sep 20 | 0 | -11 | 4 | 8 |
30 Jun 20 | 0 | -10 | 4 | 6 |
31 Mar 20 | 0 | -10 | 4 | 7 |
31 Dec 19 | 0 | -11 | 4 | 8 |
30 Sep 19 | 0 | -10 | 3 | 6 |
30 Jun 19 | 1 | -9 | 3 | 7 |
31 Mar 19 | 1 | -8 | 3 | 6 |
31 Dec 18 | 1 | -6 | 2 | 5 |
30 Sep 18 | 1 | -5 | 3 | 4 |
30 Jun 18 | 0 | -4 | 2 | 3 |
31 Mar 18 | 0 | -4 | 2 | 3 |
31 Dec 17 | 0 | -4 | 1 | 3 |
30 Sep 17 | 0 | -4 | 1 | 3 |
30 Jun 17 | 0 | -4 | 1 | 3 |
31 Mar 17 | 0 | -3 | 1 | 3 |
31 Dec 16 | 0 | -2 | 1 | 2 |
30 Sep 16 | 0 | -2 | 1 | 2 |
30 Jun 16 | 0 | -2 | 1 | 1 |
31 Mar 16 | 0 | -1 | 0 | 1 |
31 Dec 15 | 0 | -2 | 0 | 1 |
30 Sep 15 | 0 | -2 | 1 | 1 |
30 Jun 15 | 0 | -2 | 1 | 1 |
31 Mar 15 | 0 | -3 | 1 | 2 |
31 Dec 14 | 0 | -5 | 1 | 3 |
30 Sep 14 | 0 | -5 | 1 | 4 |
30 Jun 14 | 0 | -6 | 1 | 5 |
31 Mar 14 | 0 | -7 | 1 | 6 |
31 Dec 13 | 0 | -7 | 1 | 6 |
30 Sep 13 | 0 | -9 | 1 | 8 |
Quality Earnings: DMAC is currently unprofitable.
Growing Profit Margin: DMAC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DMAC is unprofitable, and losses have increased over the past 5 years at a rate of 15.7% per year.
Accelerating Growth: Unable to compare DMAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DMAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: DMAC has a negative Return on Equity (-37.96%), as it is currently unprofitable.